Sign in
Active, not recruitingNo phase

Alpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease

Key facts

Who runs it
Columbia University
Where
Birmingham, Boston, Chapel Hill, Charleston, Chicago, Denver, Los Angeles, New York, and Salt Lake City, United StatesSee the 9 sites
Trial code
Status
Active, not recruiting
People taking part
286 people enrolled
Started
23 Mar 2022
Expected to end
Jan 2027
Type of study
Observational, 2 groups
Record updated
16 January 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Males and females aged 18 years and older
  • Patients with known Alpha-1 Anti-trypsin deficiency (PiZZ)
  • Be an existing member of the Alpha-1 Foundation Clinical Cohort (Alpha-1 Foundation Research Registry)
  • Willingness to perform study procedures of Chest CT, blood biomarker determination, questionnaire completion, and lung function testing

Who cannot take part

  • Previous lung or liver transplantation or currently on the transplant list
  • COPD exacerbation or other pulmonary infection within 6 weeks of baseline visit
  • AATD non-PiZZ status, including carriers
  • Pregnancy at the time of the screening visit

Where in United States

  • University of Alabama at BirminghamBirmingham, United States
  • Boston UniversityBoston, United States
  • University of North CarolinaChapel Hill, United States
  • Medical University of South CarolinaCharleston, United States
  • University of ChicagoChicago, United States
  • National Jewish HealthDenver, United States
  • University of California, Los AngelesLos Angeles, United States
  • Columbia UniversityNew York, United States
  • University of UtahSalt Lake City, United States

About the trial

What the trial wants to find out

Alpha-1 Anti-trypsin Deficiency (AATD) is a genetic disease with lung and liver disease presentations. The purpose of this study is to examine the density of the lung as measured by chest computed tomography (CT) and determine if existing emphysema predicts changes in the rate of subsequent emphysema or changes in CT, serum or plasma biomarkers of interest. The overarching goal is to develop biomarkers that can be used in interventional trials since lung function changes do not typically inform disease progression in AATD.

The 2 groups in the trial

  • Moderate to Advanced Emphysema

    Patients with moderate or advanced Emphysema as measured by baseline inspiratory PERC-15 below the study median

  • Minimal Emphysema

    Patients with minimal emphysema as measured by baseline inspiratory PERC-15 above the study median

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Alpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease - Alpha-1 Biomarker Research Consortium (A1BC)
Record updated
16 January 2026